Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2Sarcoma 1

Conditions

Unspecified Adult Solid Tumor, Protocol Specific 2Medulloblastoma 2Glioblastoma 2Ependymoma 2Brain Neoplasms 2Recurrence 1Pancreatic Neoplasms 1Neuroectodermal Tumors, Primitive 1Melanoma 1Lung Neoplasms 1Gliosarcoma 1Glioma 1Diffuse Intrinsic Pontine Glioma 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

Temozolomide 11Filgrastim 5Magnetic Resonance Spectroscopy 4Cyclophosphamide 4Carmustine 4Thiotepa 3Radiation 3Etoposide 3Carboplatin 3Azacitidine 3Automobiles 3sargramostim 2Radiotherapy 2Peripheral Blood Stem Cell Transplantation 2ONC206 2O(6)-benzylguanine 2Nivolumab 2Melphalan 2Immunohistochemistry 2Imiquimod 2Imatinib Mesylate 2Granulocyte Colony-Stimulating Factor 22-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole 22,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 21-methyltryptophan 2vitespin 1veliparib 1vatalanib 1trametinib 1thymoglobulin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Ependymoma × 1-methyltryptophan × Clear all
NCT05106296 2026-01-09

Chemo-immunotherapy Using Ibrutinib Plus Indoximod for Patients With Pediatric Brain Cancer

Augusta University

Phase 1 Recruiting
37 enrolled
CNS

Brain Neoplasms, Ependymoma, Glioblastoma, Medulloblastoma, Neuroectodermal Tumors, Primitive

NCT02502708 2020-06-04

Study of the IDO Pathway Inhibitor, Indoximod, and Temozolomide for Pediatric Patients With Progressive Primary Malignant Brain Tumors

Lumos Pharma

Phase 1 Completed
81 enrolled
CNSSarcoma

Diffuse Intrinsic Pontine Glioma, Brain Neoplasms, Ependymoma, Glioblastoma, Glioma, Medulloblastoma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡